isirv Antiviral Group
AVG Home
|
AVG Webinar Series
AVG Webinar series You can listen to the recordings from the AVG webinars which have taken place to date via the links below: 25 October 2022: Treatments/Antiviral Therapeutics - link to the recording 24 January 2023: Antiviral Resistance - link to the recording 20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording 30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording Details of dates and topics for 2024 will be posted soon – watch this space!
7th AVG Conference (in-person)
We’ve had some great feedback….
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Recent AVG Events Therapeutics for COVID-19, a special virtual conference, 6-8 October 2020
The 3-day programme addressed the latest advances in the development of antivirals and other therapeutics for use against COVID-19 and possibilities for improved clinical management. Oral and e-poster presentations are available. Read more
AVG Polymerase Inhibitor Resistance Meeting, at the Offices of the Task Force for Global Health, Atlanta, USA, 7-8 August 2019
The participants at this small specialist meeting, including public health, academic and corporate representatives who are conducting studies on the new antivirals targeting the influenza RNA polymerase, met to discuss the impact of resistance to these inhibitors. A report of the meeting is incorporated in an Assessment of the Current State of the Art report published in Antiviral Research and now on the AVR journal web site as a highlighted article. Read more
Antiviral News
Latest… Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023... read more A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023... read more Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study (miniSTONE-2)... read more The combined effect of oseltamivir and favipiravir on influenza A virus evolution in patients hospitalized with severe influenza... read more Endonuclease and other Polymerase Inhibitors
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses... read more
New Drug Discovery
Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors... read more
Clinical Trials & Case Studies
Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases... read more
Advanced virtual screening enables the discovery of a host-targeting and broad-spectrum antiviral agent...read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
|
Visit us on:
  Quick links:
Contact AVG:Email:avg@isirv.org |
